Since 2008, our company has gained extensive technical expertise in prostaglandin synthesis. We established a high-potent active pharmaceutical ingredients (HP-APIs) GMP facility in Qingyuan, and R&D center in Guangzhou. Based on this platform, we not only produce prostaglandin APIs but also develop innovative new drugs.
Based on the Drug-Drug Conjugate (DDC) plus prodrug technology platform, with artificial intelligence and synthetic biology, our current innovative drug development focuses on the following therapeutic areas: glaucoma, pulmonary arterial hypertension, hair restoration and aesthetics, female sexual arousal disorder, and peripheral vascular diseases such as diabetic foot.
|
|